Fiche publication
Date publication
août 2021
Journal
Diagnostics (Basel, Switzerland)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr LOFFROY Romaric
Tous les auteurs :
Lanouzière M, Varbédian O, Chevallier O, Griviau L, Guillen K, Popoff R, Aho-Glélé SL, Loffroy R
Lien Pubmed
Résumé
The aim of our study was to assess the efficacy of a computed tomography (CT)-Navigation™ electromagnetic system compared to conventional CT methods for percutaneous lung biopsies (PLB). In this single-center retrospective study, data of a CT-Navigation™ system guided PLB (NAV-group) and conventional CT PLB (CT-group) performed between January 2017 and February 2020 were reviewed. The primary endpoint was the diagnostic success. Secondary endpoints were technical success, total procedure duration, number of CT acquisitions and the dose length product (DLP) during step ∆1 (from planning to initial needle placement), step ∆2 (progression to target), and the entire intervention (from planning to final control) and complications. Additional parameters were recorded, such as the lesion's size and trajectory angles. Sixty patients were included in each group. The lesions median size and median values of the two trajectory angles were significantly lower (20 vs. 29.5 mm, = 0.006) and higher in the NAV-group (15.5° and 10° vs. 6° and 1°; < 0.01), respectively. Technical and diagnostic success rates were similar in both groups, respectively 95% and 93.3% in the NAV-group, and 93.3% and 91.6% in the CT-group. There was no significant difference in total procedure duration ( = 0.487) and total number of CT acquisitions ( = 0.066), but the DLP was significantly lower in the NAV-group ( < 0.01). There was no significant difference in complication rate. For PLB, CT-Navigation™ system is efficient and safe as compared to the conventional CT method.
Mots clés
CT-guided biopsy, Imactis, computed tomography, navigation system, percutaneous lung biopsy
Référence
Diagnostics (Basel). 2021 Aug 25;11(9):
